rs1057519731
|
|
|
0.720 |
GeneticVariation |
BEFREE |
We found that the acquired MEK1-C121S mutation in BRAF-V600E mutant melanoma conferred resistance to both vemurafenib and selumetinib but not E6201.
|
24448821 |
2014 |
rs1057519731
|
|
|
0.720 |
GeneticVariation |
BEFREE |
Our data confirming that MEK2(C125S), but not the synonymous MEK1(C121S) protein, confers resistance to combination therapy highlight the functional differences between these kinases and the preponderance of MEK2 mutations in combination therapy-resistant melanomas.
|
25452114 |
2014 |
rs397516792
|
|
|
0.720 |
GeneticVariation |
BEFREE |
One such mutation, MEK1(P124L), was identified in a resistant metastatic focus that emerged in a melanoma patient treated with AZD6244.
|
19915144 |
2009 |
rs397516792
|
|
|
0.720 |
GeneticVariation |
BEFREE |
Furthermore, MEK1(P124Q/S) mutations were shown to have independent kinase activity and introduction of these mutations into a BRAF-mutant melanoma cell line diminished inhibition of ERK phosphorylation by dabrafenib and enhanced clonogenic survival in the presence of dabrafenib compared with cells ectopically expressing wild-type MEK1.
|
25370473 |
2015 |
rs1057519729
|
|
C |
0.700 |
GeneticVariation |
CLINVAR |
MEK1 mutations confer resistance to MEK and B-RAF inhibition.
|
19915144 |
2009 |
rs1057519729
|
|
C |
0.700 |
GeneticVariation |
CLINVAR |
Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma.
|
23569304 |
2013 |
rs1057519805
|
|
C |
0.700 |
GeneticVariation |
CLINVAR |
Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors.
|
23614898 |
2013 |
rs1057519805
|
|
C |
0.700 |
GeneticVariation |
CLINVAR |
MEK1 mutations confer resistance to MEK and B-RAF inhibition.
|
19915144 |
2009 |
rs121908596
|
|
A |
0.700 |
GeneticVariation |
CLINVAR |
MEK1 mutations confer resistance to MEK and B-RAF inhibition.
|
19915144 |
2009 |
rs397516790
|
|
G |
0.700 |
GeneticVariation |
CLINVAR |
Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma.
|
23569304 |
2013 |
rs727504317
|
|
A |
0.700 |
GeneticVariation |
CLINVAR |
Prospective enterprise-level molecular genotyping of a cohort of cancer patients.
|
25157968 |
2014 |
rs869025608
|
|
C |
0.700 |
GeneticVariation |
CLINVAR |
Phase II trial of MEK inhibitor selumetinib (AZD6244, ARRY-142886) in patients with BRAFV600E/K-mutated melanoma.
|
23444215 |
2013 |
rs869025608
|
|
T |
0.700 |
GeneticVariation |
CLINVAR |
Phase II trial of MEK inhibitor selumetinib (AZD6244, ARRY-142886) in patients with BRAFV600E/K-mutated melanoma.
|
23444215 |
2013 |
rs1057519856
|
|
|
0.020 |
GeneticVariation |
BEFREE |
We found that the acquired MEK1-C121S mutation in BRAF-V600E mutant melanoma conferred resistance to both vemurafenib and selumetinib but not E6201.
|
24448821 |
2014 |
rs1057519856
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Our data confirming that MEK2(C125S), but not the synonymous MEK1(C121S) protein, confers resistance to combination therapy highlight the functional differences between these kinases and the preponderance of MEK2 mutations in combination therapy-resistant melanomas.
|
25452114 |
2014 |
rs1057519731
|
|
C |
0.720 |
CausalMutation |
CLINVAR |
Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma.
|
22197931 |
2011 |
rs1057519731
|
|
C |
0.720 |
CausalMutation |
CLINVAR |
Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling.
|
21383288 |
2011 |
rs1057519731
|
|
C |
0.720 |
CausalMutation |
CLINVAR |
We found that the acquired MEK1-C121S mutation in BRAF-V600E mutant melanoma conferred resistance to both vemurafenib and selumetinib but not E6201.
|
24448821 |
2014 |
rs1057519731
|
|
C |
0.720 |
CausalMutation |
CLINVAR |
Preexisting MEK1 exon 3 mutations in V600E/KBRAF melanomas do not confer resistance to BRAF inhibitors.
|
22588879 |
2012 |
rs397516792
|
|
T |
0.720 |
CausalMutation |
CLINVAR |
COT drives resistance to RAF inhibition through MAP kinase pathway reactivation.
|
21107320 |
2010 |
rs397516792
|
|
T |
0.720 |
CausalMutation |
CLINVAR |
One such mutation, MEK1(P124L), was identified in a resistant metastatic focus that emerged in a melanoma patient treated with AZD6244.
|
19915144 |
2009 |
rs397516792
|
|
T |
0.720 |
CausalMutation |
CLINVAR |
Prospective enterprise-level molecular genotyping of a cohort of cancer patients.
|
25157968 |
2014 |
rs397516792
|
|
T |
0.720 |
CausalMutation |
CLINVAR |
Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma.
|
22197931 |
2011 |
rs1057519728
|
|
C |
0.700 |
CausalMutation |
CLINVAR |
Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma.
|
22197931 |
2011 |
rs1057519730
|
|
G |
0.700 |
CausalMutation |
CLINVAR |
Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma.
|
22197931 |
2011 |